Doseology Sciences, Inc. (TSE:MOOD)
:MOOD
Want to see TSE:MOOD full AI Analyst Report?
Top Page
Doseology Sciences
(MOOD)
Select Model
Select Model
Rating:42Neutral
Price Target:
C$0.26
▼(-50.19% Downside)
Action:Reiterated
Date:06/19/26
The score is held down primarily by weak financial performance (small/declining revenue, ongoing losses, and negative operating/free cash flow) and bearish technicals (price below all key moving averages with negative MACD). The debt-free balance sheet is a positive, but valuation signals are not supportive due to negative earnings and no dividend data.
Positive Factors
Debt-free balance sheet
A near-zero debt profile and strong equity base provide durable financial flexibility, lowering default risk and preserving optionality for partnerships, R&D or targeted bolt-on deals. This structural strength reduces leverage constraints over the next several quarters even if profits remain weak.
Negative Factors
Small, declining revenue
Volatile and shrinking revenue undermines scale economics and makes fixed-cost absorption harder. Without sustained top-line growth, the company cannot leverage its product pipeline or reduce unit costs, keeping margins pressured and external funding likely necessary.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A near-zero debt profile and strong equity base provide durable financial flexibility, lowering default risk and preserving optionality for partnerships, R&D or targeted bolt-on deals. This structural strength reduces leverage constraints over the next several quarters even if profits remain weak.
Read all positive factors
Doseology Sciences (MOOD) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$2.20M
Dividend YieldN/A
Average Volume (3M)1.79K
Price to Earnings (P/E)―
Beta (1Y)-3.26
Revenue Growth73.76%
EPS Growth-108.30%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.08
Shares Outstanding8,011,621
10 Day Avg. Volume3,383
30 Day Avg. Volume1,793
Financial Highlights & Ratios
PEG Ratio-0.49
Price to Book (P/B)3.46
Price to Sales (P/S)113.73
P/FCF Ratio-14.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Doseology Sciences Business Overview & Revenue Model
Company Description
Based in Kelowna, Canada, Doseology Sciences Inc. specializes in the cultivation and extraction of ingredients for health and medicinal products across the country. The company dedicates itself to the research, development, and online distribution...
How the Company Makes Money
null...
Doseology Sciences Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 42.56K | 98.52K | 43.09K | 16.05K | 0.00 |
| Gross Profit | 18.89K | 72.09K | 41.29K | -148.38K | -92.83K |
| EBITDA | -471.61K | -319.48K | -1.78M | -1.72M | -1.47M |
| Net Income | -447.79K | -339.85K | -1.78M | -1.94M | -1.63M |
Balance Sheet | |||||
| Total Assets | 1.49M | 1.10M | 1.40M | 3.87M | 5.99M |
| Cash, Cash Equivalents and Short-Term Investments | 1.43M | 1.06M | 1.30M | 1.87M | 3.73M |
| Total Debt | 0.00 | 0.00 | 50.27K | 746.10K | 687.54K |
| Total Liabilities | 94.11K | 82.49K | 99.19K | 871.51K | 3.41M |
| Stockholders Equity | 1.40M | 1.02M | 1.30M | 3.00M | 2.58M |
Cash Flow | |||||
| Free Cash Flow | -342.24K | -235.12K | -481.05K | -1.72M | -2.54M |
| Operating Cash Flow | -342.24K | -235.12K | -481.05K | -1.71M | -2.37M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -7.88K | -26.05K |
| Financing Cash Flow | 711.68K | -6.14K | -91.88K | -140.08K | 5.79M |
Doseology Sciences Technical Analysis
Negative
0.53
Price Trends
0.44
Negative
0.55
Negative
0.56
Negative
Market Momentum
-0.07
Negative
43.97
Neutral
48.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MOOD, the sentiment is Negative. The current price of 0.53 is above the 20-day moving average (MA) of 0.32, above the 50-day MA of 0.44, and below the 200-day MA of 0.56, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 43.97 is Neutral, neither overbought nor oversold. The STOCH value of 48.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MOOD.
Doseology Sciences Peers Comparison
UnderperformOutperform
Sector (51)
TSE:MOOD
Doseology Sciences
0.28
-0.53
-65.63%
TSE:DOSE
Rapid Dose Therapeutics Corp
0.10
-0.10
-50.00%
TSE:MYND
MYND Life Sciences
0.07
0.00
0.00%
TSE:IBO
Universal Ibogaine Inc
0.01
-0.01
-50.00%
TSE:MBIO
Mindbio Therapeutics Corp.
0.43
-3.57
-89.25%
Doseology Sciences Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Doseology launches $2 million private placement to fund oral stimulant pouch rollout
Positive
Mar 30, 2026
Doseology Sciences Inc. has arranged a non-brokered private placement of up to 3,225,806 units at $0.62 per unit to raise as much as $2 million, with each unit comprising one common share and a warrant exercisable at $1.00 for two years, subject t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.